Read before the Boston Society for Medical Improvement, December 9, 1889.
In patients with type 2 diabetes (T2D), the use of GLP-1 receptor agonists (RAs) is not associated with an increased risk for most serious gastrointestinal (GI) or hepatobiliary outcomes over 5 years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results